Rigel Pharmaceuticals | RIGL - Net Income


Rigel Pharmaceuticals reported $12.42M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agenus USD -25.27M 20.59M Mar/2025
Amgen USD 1.33B 1.88B Dec/2025
Anika Therapeutics USD -4.87M 16.99M Mar/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Veracyte USD 41.15M 22.01M Dec/2025